SCHEMBL3887047

SCHEMBL3887047

CCCN(CCOc1ccc(N)c(OC)n1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 3/20 0.37
CYP2D6 P10635 3/20 0.37
SCN1A P35498 3/20 0.37
SCN2A Q99250 3/20 0.37
SCN3A Q9NY46 3/20 0.37
KCNH2 Q12809 3/20 0.37
HRH3 Q9Y5N1 3/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TSHR P16473 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
HIF1A Q16665 1/20 0.37
RAD52 P43351 1/20 0.36
MAOA P21397 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032439 0.85 SSTR4 (0.33) MEN1KMT2ACYP1A2CYP2D6SCN1A
SCHEMBL3896618 0.81 GABRG2 (0.32) LPAR1LPAR5
SCHEMBL1031781 0.80 BCHE (0.41) MEN1KMT2ATSHRSIGMAR1
SCHEMBL3889926 0.77 MAPT (0.39) MEN1KMT2ACYP1A2CYP2D6SCN1A
SCHEMBL26087681 0.72 PIK3CA (0.41) POLBTDP1TSHRALDH1A1LMNA
SCHEMBL21582525 0.72 MAPT (0.39) MEN1KMT2APOLBTDP1TSHR
SCHEMBL3899401 0.71 KDM4E (0.42) KMT2AKCNH2MAOAALDH1A1KDM4E
SCHEMBL1027137 0.71 SSTR4 (0.34) CYP1A2CYP2D6SCN1ASCN2ASCN3A
SCHEMBL23620154 0.71 APP (0.36) POLBTDP1
SCHEMBL30991293 0.71 APP (0.36) POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-01-14 EP disclosed
WO-2007118859-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed